ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Conditions:   Acute Hepatic Porphyria;   Acute Intermittent Porphyria;   Porphyria, Acute Intermittent;   Acute Porphyria;   Hereditary Coproporphyria (HCP);   Variegate Porphyria (VP);   ALA Dehydratase Deficient Porphyria (ADP) Interventions:   Drug: Givosiran;   Drug: Placebo Sponsor:   Alnylam Pharmaceuticals Recruiting

Source: ClinicalTrials.gov - November 9, 2017 Category: Research Source Type: clinical trials